NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

London stocks gain as AstraZeneca, Indivior jump

Published 01/26/2021, 04:31 PM
Updated 01/26/2021, 04:40 PM
© Reuters.
UK100
-
AZN
-
RKT
-
RR
-
FTMC
-
FTNMX201020
-
INDV
-

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)
* FTSE 100 rises 0.6%, FTSE 250 adds 0.2%

Jan 26 (Reuters) - British stocks rose on Tuesday after
drugmaker AstraZeneca denied reports that its COVID-19 vaccine
was less effective in the elderly population, while Indivior
surged after its former parent withdrew a $1.4 billion legal
claim.
The blue-chip FTSE 100 index .FTSE climbed 0.5%, with
healthcare stocks .FTNMX4530 leading the gains, while the
domestically focussed mid-cap index .FTMC added 0.2%.
Drugmaker AstraZeneca AZN.L gained 0.7% and was the top
boost to the FTSE 100 after denying reports that its COVID-19
vaccine is not very effective for people aged over 65.
German media reports said officials fear the vaccine may not
be approved in the European Union for use in the elderly.
However, limiting gains was a jump in Britain's unemployment
rate to 5.0%, its highest since 2016, as the COVID-19 pandemic
continued to take its toll on the economy, official figures
showed. Britain's Rolls-Royce RR.L tumbled 7% after it downgraded
expectations for how much its engines would fly this year and
warned of a big cash outflow, blaming extra travel restrictions
to stop the spread of a new COVID-19 variant. Indivior INDV.L jumped 10.1% to the top of the FTSE 250
index after it said late on Monday that former parent Reckitt
Benckiser RB.L would withdraw a $1.4 billion claim against the
company.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.